Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 4D Molecular Therapeutics Inc (NQ: FDMT ) 8.350 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about 4D Molecular Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference June 06, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting June 04, 2024 • 24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden... From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conferences June 03, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) March 01, 2024 Via Benzinga What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics February 07, 2024 Via Benzinga 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference May 30, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights May 09, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conference May 07, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Why Is 4D Molecular (FDMT) Stock Up 85% Today? February 05, 2024 Investors in 4D Molecular Therapeutics and FDMT stock are seeing big gains today, as the stock surges 80% on positive trial results. Via InvestorPlace 4DMT Announces Presentations at ARVO 2024 Annual Meeting May 01, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation April 18, 2024 Via Benzinga Topics ETFs 4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease March 28, 2024 4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and... Via Benzinga 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis March 28, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conferences March 04, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Reports Full Year 2023 Financial Results and Operational Highlights February 29, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024 February 12, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? February 08, 2024 Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. Via Benzinga Why 4D Molecular Therapeutics (FDMT) Stock Is Diving February 07, 2024 4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized underwritten public offering. Via Benzinga 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock February 06, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast February 06, 2024 4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70. Via Benzinga 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock February 05, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Crude Oil Moves Higher; Caterpillar Posts Upbeat Earnings February 05, 2024 U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,450.28 while the NASDAQ fell 0.11% to 15,612.52. The... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 12 Health Care Stocks Moving In Monday's Intraday Session February 05, 2024 Via Benzinga Gold Moves Lower; ISM Services PMI Beats Estimates February 05, 2024 U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,253.72 while the NASDAQ fell 0.86% to 15,493.97. The... Via Benzinga Topics Stocks Exposures US Equities Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 05, 2024 Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... Via Benzinga 4D Molecular Therapeutics Inc. (NASDAQ: FDMT) Leading the Way in Monday Trading Based on Percentage Gain February 05, 2024 Via Investor Brand Network Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? February 05, 2024 4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity. Via Benzinga Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday February 05, 2024 U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. Via Benzinga Topics Stocks Exposures US Equities Dow Tumbles 150 Points; McDonald's Sales Miss Views February 05, 2024 U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow traded down 0.41% to 38,494.03 while the NASDAQ fell... Via Benzinga Topics Earnings Stocks Exposures Financial US Equities < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
